Determining the optimal conditioning regimen for patients with primary central nervous system lymphoma undergoing autologous hematopoietic cell transplantation.
Study #: LY19-02
Study Status: Published
Presentation(s)
2020, ASH (Oral)
Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant.
Citation
Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS.
JAMA Oncology. 2021, Jul 01: 7(7): 7(7):993-1003. doi: 10.1001/jamaoncol.2021.1074. Epub 2021, May 06. PMCID:PMC8283558.
PubMed
PMID: 33956047
Abstract